单倍体相合与HLA相合同胞供者移植联合PTCy预防:HLA因素与供者年龄考量
本研究比较单倍体相合造血细胞移植(n=1052)与HLA相合同胞供者移植(n=400)联合移植后环磷酰胺(PTCy)预防移植物抗宿主病的效果。多变量分析显示两组总生存、非复发死亡和复发风险相似。在老年受者中,年轻且B-leader匹配的单倍体供者组总生存优于年长MSD组,年轻DRB1错配单倍体供者组复发风险更低。
要点
- 单倍体相合移植联合PTCy的总生存、非复发死亡和复发风险与HLA相合同胞供者移植相似。
- 在≥50岁受者中,年轻(<35岁)B-leader匹配单倍体供者组总生存优于年长(≥50岁)MSD组。
- 在≥50岁受者中,年轻DRB1错配单倍体供者组复发风险低于年长MSD组。
核心结论
- 单倍体相合移植联合PTCy可能提供与HLA相合同胞供者移植联合PTCy相当的结局。
- 在老年患者中,年轻且B-leader匹配的单倍体供者可能优于年长的HLA相合同胞供者。
- 上述发现需在更大数据集中验证。
研究设计与样本
- 比较单倍体相合移植(n=1052)与HLA相合同胞供者移植(n=400)的回顾性研究,两组均采用基于PTCy的移植物抗宿主病预防。
主要发现
- 多变量分析中,单倍体相合组与MSD组的总生存(HR 0.94;95%CI 0.78-1.14;P=.54)、非复发死亡(HR 0.98;95%CI 0.72-1.32;P=.87)和复发(HR 0.87;95%CI 0.70-1.08;P=.20)相似。
- 供者年龄较轻是总生存改善的显著预测因素。
- 在≥50岁受者中,年轻(<35岁)B-leader匹配单倍体供者组总生存显著优于年长(≥50岁)MSD组(HR 0.65;95%CI 0.48-0.90;P=.009)。
- 在≥50岁受者中,年轻DRB1错配单倍体供者组复发风险显著低于年长MSD组(HR 0.63;95%CI 0.46-0.87;P=.004)。
临床怎么用
- 作者认为,单倍体相合移植联合PTCy可能提供与HLA相合同胞供者移植联合PTCy相当的结局。
- 作者认为,在老年患者中,年轻且B-leader匹配的单倍体供者可能优于年长的HLA相合同胞供者。
- 作者指出,上述发现需在更大数据集中验证。
局限性
- 原文指出这些发现需在更大数据集中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA-matched sibling donors (MSDs) are preferred for hematopoietic cell transplantation (HCT). However, the use of alternative donors, especially haploidentical, is increasing, as is our understanding of the impact of HLA factors such as B-leader and DRB1-matching on its outcomes. Yet, data comparing these donor types, particularly considering these HLA factors, is lacking. Herein, we compared haploidentical-HCT (n = 1052) with MSD-HCT (n = 400), both with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis. In multivariate analysis, haploidentical group had similar overall survival (OS; hazard ratio (HR), 0.94; 95% confidence interval [CI], 0.78-1.14; P = .54), nonrelapse mortality (HR, 0.98; 95% CI, 0.72-1.32; P = .87), and relapse (HR, 0.87; 95% CI, 0.70-1.08; P = .20) as the MSD group. Younger donor age was a significant predictor of improved OS. Next, we directly compared the outcomes of "younger" haploidentical (donor age <35 years, n = 347) vs an "older" MSD (donor age ≥50 years, n = 143) in older recipients (patient age ≥50 years). Patients with younger haploidentical B-leader-matched donors had significantly superior OS (HR, 0.65; 95% CI, 0.48-0.90; P = .009) than the older MSD group. Additionally, patients with younger DRB1-mismatched haploidentical donors (HR, 0.63; 95% CI, 0.46-0.87; P = .004) had significantly lower risk of relapse than older MSDs. Our study suggests that haploidentical-HCT may offer comparable outcomes to MSD-PTCy HCT. Moreover, among older patients, a younger haploidentical B-leader-matched donor might be preferable to an older MSD. These findings need validation in larger data sets.
引用
- Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024. PMID: 39167765. doi:10.1182/bloodadvances.2024013853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。